MYCOF News and Press, New Age Brands From 01/10/22

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the co...

The new serotonin receptor model (5-HT 2A ) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules. DENVER, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“...

VANCOUVER, British Columbia, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and add...

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital h...

Researchers at the University of Pennsylvania’s School of Medicine have discovered that a program which was designed to make buprenorphine administration timely and easy has increased the use of the treatment in hospital emergency departments significantly. Buprenorphine is a drug t...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) , a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “ Gamechangers LIVE .” The podcast series shines a s...

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Joshua Bartch , Co-Founder, Chairman and CEO of Mydecine Innovations Gro...

Patients with cancer have a high risk of suicidal ideation and suicide, in particular patients in the advanced stages. These individuals often experience a loss of meaning in life and existential distress, which isn’t easily remedied through the use of pharmacological treatments. Ho...

Dementia is known to affect an individual’s mental processes, leading to loss of cognitive functioning . It is typically caused by brain injury or disease and is marked by impaired reasoning, changes in personality and memory disorders. In its later stages, the disease kills off the ...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) , a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed ...